Indeed, we found, by RT-PCR and Western blot, an increase of both GFAP and S100B expression in placebo-treated 3×Tg-AD mice in comparison with placebo-treated non-Tg mice (P < 0.05) (Figures 4(a), 4(b), 4(c), 4(f), 4(g), and 4(h)). Here, GFAP is linked to Alzheimer disease.